17-10-10　ⓔ文献

  1. Swerdlow SH, Campo E, et al eds: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th ed), IARC, 2017.

  2. Marafioti T, Hummel M, et al: Origin of nodular lymphocyte–predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med, 1997; 337: 453–458.

  3. Ohno T, Stribley JA, et al: Clonality in nodular lymphocyte–predominant Hodgkin’s disease. N Engl J Med, 1997; 337: 459–465.

  4. Kanzler H, Kuppers R, et al: Hodgkin and Reed–Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med, 1996; 184: 1495–1505.

  5. Cheson BD, Fisher RI, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non–Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 2014; 32: 3059–3068.

  6. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med, 1998; 339: 1506–1514.

  7. Canellos GP, Anderson JR, et al: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 1992; 327: 1478–1484.

  8. Specht L, Yahalom J, et al: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys, 2014; 89: 854–862.

  9. Bonadonna G, Bonfante V, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early–stage Hodgkin’s disease: long–term results. J Clin Oncol, 2004; 22: 2835–2841.

  10. Eich HT, Diehl V, et al: Intensified chemotherapy and dose–reduced involved–field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol, 2010; 28: 4199–4206.

  11. Engert A, Plutschow, A et al: Reduced treatment intensity in patients with early–stage Hodgkin’s lymphoma. N Engl J Med, 2010; 363: 640–652.

  12. Canellos GP, Anderson JR, et al: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 1992; 327: 1478–1484.

  13. Canellos GP, Niedzwiecki D, et al: Long–term follow–up of survival in Hodgkin's lymphoma. N Engl J Med, 2009; 361: 2390–2391.

  14. Younes A, Connors JM, et al: Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open–label, dose–escalation study. Lancet Oncol, 2013; 14: 1348–1356.

  15. Gallamini A, Hutchings M, et al: Early interim 2–[18F]fluoro–2–deoxy–D–glucose positron emission tomography is prognostically superior to international prognostic score in advanced–stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol, 2007; 25: 3746–3752.

  16. Schmitz N, Pfistner B, et al: Aggressive conventional chemotherapy compared with high–dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet, 2002; 359: 2065–2071.

  17. Younes A, Bartlett NL, et al: Brentuximab vedotin (SGN–35) for relapsed CD30–positive lymphomas. N Engl J Med, 2010; 363: 1812–1821.

  18. Ansell SM, Lesokhin AM, et al: PD–1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med, 2015; 372: 311–319.

  19. Chen R, Zinzani PL, et al: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol, 2017; 35: 2125–2132.